Sumitomo Pharma Statistics
Total Valuation
Sumitomo Pharma has a market cap or net worth of 5.83 billion. The enterprise value is 7.13 billion.
| Market Cap | 5.83B |
| Enterprise Value | 7.13B |
Important Dates
The last earnings date was Friday, January 30, 2026.
| Earnings Date | Jan 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 397.29M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 13.80% |
| Float | 183.27M |
Valuation Ratios
The trailing PE ratio is 8.31.
| PE Ratio | 8.31 |
| Forward PE | n/a |
| PS Ratio | 2.02 |
| PB Ratio | 3.16 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 19.42 |
| P/OCF Ratio | 17.16 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.52, with an EV/FCF ratio of 23.73.
| EV / Earnings | 10.15 |
| EV / Sales | 2.45 |
| EV / EBITDA | 8.52 |
| EV / EBIT | 10.22 |
| EV / FCF | 23.73 |
Financial Position
The company has a current ratio of 1.40, with a Debt / Equity ratio of 0.90.
| Current Ratio | 1.40 |
| Quick Ratio | 0.91 |
| Debt / Equity | 0.90 |
| Debt / EBITDA | 1.99 |
| Debt / FCF | 5.50 |
| Interest Coverage | 3.59 |
Financial Efficiency
Return on equity (ROE) is 48.39% and return on invested capital (ROIC) is 22.11%.
| Return on Equity (ROE) | 48.39% |
| Return on Assets (ROA) | 8.12% |
| Return on Invested Capital (ROIC) | 22.11% |
| Return on Capital Employed (ROCE) | 17.95% |
| Weighted Average Cost of Capital (WACC) | 7.65% |
| Revenue Per Employee | 754,638 |
| Profits Per Employee | 183,239 |
| Employee Count | 3,832 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.95 |
Taxes
| Income Tax | -95.47M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +222.00% in the last 52 weeks. The beta is 0.54, so Sumitomo Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.54 |
| 52-Week Price Change | +222.00% |
| 50-Day Moving Average | 7.17 |
| 200-Day Moving Average | 10.41 |
| Relative Strength Index (RSI) | 58.23 |
| Average Volume (20 Days) | 1,537 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sumitomo Pharma had revenue of 2.89 billion and earned 702.17 million in profits. Earnings per share was 1.77.
| Revenue | 2.89B |
| Gross Profit | 1.71B |
| Operating Income | 691.35M |
| Pretax Income | 606.70M |
| Net Income | 702.17M |
| EBITDA | 829.16M |
| EBIT | 691.35M |
| Earnings Per Share (EPS) | 1.77 |
Balance Sheet
The company has 365.61 million in cash and 1.65 billion in debt, with a net cash position of -1.29 billion.
| Cash & Cash Equivalents | 365.61M |
| Total Debt | 1.65B |
| Net Cash | -1.29B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.84B |
| Book Value Per Share | 4.64 |
| Working Capital | 536.63M |
Cash Flow
In the last 12 months, operating cash flow was 339.80 million and capital expenditures -39.45 million, giving a free cash flow of 300.35 million.
| Operating Cash Flow | 339.80M |
| Capital Expenditures | -39.45M |
| Free Cash Flow | 300.35M |
| FCF Per Share | n/a |
Margins
Gross margin is 59.24%, with operating and profit margins of 23.91% and 24.28%.
| Gross Margin | 59.24% |
| Operating Margin | 23.91% |
| Pretax Margin | 20.98% |
| Profit Margin | 24.28% |
| EBITDA Margin | 28.67% |
| EBIT Margin | 23.91% |
| FCF Margin | 10.39% |
Dividends & Yields
Sumitomo Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.00% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 12.04% |
| FCF Yield | 5.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Sumitomo Pharma has an Altman Z-Score of 1.96 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.96 |
| Piotroski F-Score | 5 |